IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies ...
GammaDelta Therapeutics has developed a pipeline of novel allogeneic cell therapies based on its Vδ1+ γδ T cell platforms for the treatment of solid tumors and beyond. Gamma delta (γδ) T ...
Zacks Small Cap Research on MSN19d
INAB: Introducing INB-600, A γδ T Cell Engager PlatformFollowing the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc. (NASDAQ:INAB) reported 2024 financial ...
IN8bio announces INB-619, a novel γδ T cell therapy platform targeting CD19, showing promise in B cell depletion with reduced side effects. IN8bio, Inc. has announced the launch of its ...
The platform’s first candidate, INB-619, targets CD19, a key marker broadly found on B cells, which play a central role in leukemias, lymphomas, and autoimmune diseases. In preclinical models, INB-619 ...
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...
Poster Title: A novel gamma-delta T cell engager platform for cancer immunotherapy Session Title: Immunology/T Cell Engagers and Novel Antibody-Based Therapies Session Date and Time: Wednesday, April ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback